Filing Flows › Zevra Therapeutics (ZVRA) › Q3 2025
Zevra Therapeutics (ZVRA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Zevra Therapeutics (ZVRA) reported revenue of $26.1M for the third quarter 2025 (Q3 2025), +605% from a year earlier and +0.7% from the quarter before. Operating margin was 15.9%, net loss $544K (2.1% of revenue).
Zevra Therapeutics, Q3 2025: revenue $26.1M (+605% year over year), operating margin 15.9%, net loss $544K, operating cash flow $4.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26.1M | +0.7% | +605% |
| Operating profit | $4.1M | — | — |
| Net earnings | −$544K | -101% | — |
| Operating cash flow | $4.7M | — | — |
| Free cash flow | $4.2M | — | — |
What changed
Revenue was $26.1M in Q3 2025, up 605% year over year and up 1% from the previous quarter.
Operating profit was $4.1M, a 15.9% margin (up 754.9 points year over year). Total costs fell 29% while revenue rose 605%. The quarter ended with a net loss of $544K, after a profit of $74.7M the previous quarter. Net interest and other expense of $5.1M was the main reason.
Operating cash flow was $4.7M. Non-cash charges added back $392K of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items added $2.1M. Capital expenditures of $554K left free cash flow of $4.2M.
Questions
What was Zevra Therapeutics' revenue in the third quarter 2025?
Zevra Therapeutics (ZVRA) reported revenue of $26.1M for the third quarter 2025 (Q3 2025), +605% from a year earlier and +0.7% from the quarter before.
Was Zevra Therapeutics profitable in the third quarter 2025?
Operating profit was $4.1M (15.9% of revenue) and net loss $544K.
Source: Zevra Therapeutics 10-Q on SEC EDGAR.